Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023

Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, announced a rescheduling of its 2022 fourth quarter and full year earnings release from March 13, 2023, to March 30, 2023. The delay is due to ongoing evaluations of the accounting treatment related to a 2022 GSK transaction, necessitating additional time for audit completion and filing their Annual Report on Form 10-K for FY 2022. Following the earnings release, Spero will hold a conference call on March 30, 2023, at 4:30 p.m. ET to discuss financial results and provide updates on its pipeline.

Positive

• Spero is actively developing novel therapies targeting multi-drug resistant infections, which may address unmet medical needs.
• The upcoming earnings release and conference call could provide investors with valuable insights into the company's financial health and future outlook.

Negative

• The delay in earnings release could raise concerns about the company's financial reporting and transparency.
• Ongoing evaluations related to the GSK transaction may indicate unresolved accounting issues that could affect investor confidence.

CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it has changed the date of its previously announced 2022 fourth quarter and full year earnings release and conference call from today, Monday, March 13, 2023 to Thursday, March 30, 2023. Spero is still evaluating the accounting treatment associated with the GSK transaction in 2022 and needs additional time to complete its audit and file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

Following issuance of the earnings release, Spero will host a conference call and live audio webcast on Thursday, March 30, 2023, at 4:30 p.m. ET to discuss its fourth quarter and full year financial results and provide an update on its business and pipeline.

A link to the audio webcast and dial-in information will be available under "Events and Presentations" in the Investor and Media section of the Company's website at www.sperotherapeutics.com before the date of the call. The archived webcast will also be available on Spero's website for 30 days following the call.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including rare diseases and multi-drug resistant bacterial infections.

• Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.
  
  
• Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved.
  
  
• Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat multi-drug resistant Gram-negative infections in the hospital setting.
  

For more information, visit https://sperotherapeutics.com.

Investor Relations Contact: 
Ted Jenkins
Vice President, Investor Relations and Strategic Finance
IR@sperotherapeutics.com
(617) 798-4039

Media Inquiries:
Lora Grassilli, Health Media Relations
Zeno Group
lora.grassilli@zenogroup.com
646-932-3735

FAQ

What is the new date for Spero Therapeutics' earnings release?

Spero Therapeutics has rescheduled its earnings release to March 30, 2023.

Why was the earnings conference call postponed for SPRO?

The postponement is due to additional time needed for the audit related to the GSK transaction from 2022.

What will Spero Therapeutics discuss in the upcoming conference call?

The call will cover Spero's fourth quarter and full year financial results and updates on its business and pipeline.

How is Spero Therapeutics addressing multi-drug resistant infections?

Spero is developing several therapies, including SPR720 and tebipenem HBr, targeted at treating multi-drug resistant bacterial infections.